Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Compounded Pain Formulations: What is the Evidence?

Author(s):  Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso

Issue:  Jul/Aug 2014 - Volume 18, Number 4
View All Articles in Issue

Page(s):  278-286

Compounded Pain Formulations: What is the Evidence? Page 1
Compounded Pain Formulations: What is the Evidence? Page 2
Compounded Pain Formulations: What is the Evidence? Page 3
Compounded Pain Formulations: What is the Evidence? Page 4
Compounded Pain Formulations: What is the Evidence? Page 5
Compounded Pain Formulations: What is the Evidence? Page 6
Compounded Pain Formulations: What is the Evidence? Page 7
Compounded Pain Formulations: What is the Evidence? Page 8
Compounded Pain Formulations: What is the Evidence? Page 9

Download in electronic PDF format for $75

Abstract:  Pain syndromes are among the most widespread, costly, and debilitating of all neurological disorders. The number of patients living with chronic pain is expected to increase with the aging population and with the rise in obesity and diabetes across the nation. This type of pain is often insensitive to the traditional pain pharmacopeia or surgical intervention. Over the last 10 years the number of prescriptions that have been compounded by pharmacists has increased dramatically. There are a number of drugs in the area of pain management that have been formulated and compounded by pharmacists to treat conditions such as diabetic neuropathy, fibromyalgia, postherpetic neuralgia, joint pain, arthritis, and a variety of other conditions. A significant portion of these compounded analgesic preparations is made up of topical/transdermal dosage forms such as gels and creams. While the efficacy and doses of these drugs in systemic dosage forms have been widely established, little is known about the permeation and efficacy of these compounds from topical/transdermal gels. This review will provide an overview of chronic pain as a disease, the mechanisms of chronic pain, current treatment approaches to chronic pain, and a discussion of the drugs that are typically compounded into these topical formulations and studied in clinical trials.

Related Keywords: Scott Asbill, PhD, Sarah M. Sweitzer, PhD, Shuler Spigener BSc, Alfonso Romero-Sandoval, MD, PhD, chronic pain, inflammation, inflammatory pain, neuropathic pain, neuropathy, quality of life, mental disturbances, pain mechanisms, nonsteroidal anti-inflammatory drugs, NSAID, topical preparations, analgesic, analgesia, pain control, pain relief, anticonvulsants, GABA receptors, cyclo-oxygenase inhibitors, COX, antidepressants, neurotransmitter uptake inhibitors, serotonin, norepinephrine, opioids, mu opioid receptors, N-methyl-D-aspartate receptors, NMDA receptor antagonists, glutamate blockers, corticosteroids, nerve compression, nerve hyperexcitability, cannabinoids, THC, marijuana, selective CB1 inhibitors, alternative treatments, muscle relaxants, baclofen, cyclobenzaprine, gabapentin, amitriptyline, clinical studies, literature review


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Compounded Pain Formulations: What is the Evidence?
Asbill Scott
, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
Jul/Aug 2014
Pg. 278-286

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Analgesic Efficacy and Transdermal Penetration of Topical Gabapentin Creams: Finding an Optimal Dose and Pre-treatment Time
Heustess Allie
, Spigener Shuler, Sweitzer Sarah, Romero-Sandoval Alfonso, Asbill Scott
Mar/Apr 2015
Pg. 167-173

Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
May/Jun 2010
Pg. 200-203

Clinical Nuggets and Pearls: Chronic Neuropathic Pain and Opioid Tolerance
Jones Marty
Jan/Feb 2002
Pg. 4-6

Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M
, Rivera Gerard, Balthasar Jan, Florea Naomi
Jul/Aug 2015
Pg. 295-300

Topical Ketamine: A Review of the History, Mechanisms, Uses, Safety, and Future
Rabi Joseph
Mar/Apr 2016
Pg. 107-113

Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Jones Marty
Jan/Feb 2000
Pg. 6-15

PostScription: Treatment of Chronic Pain with Methadone or Levorphanol
McNulty Jack P
Mar/Apr 2006
Pg. 159-160

Skin Permeation and Antinociception of Compounded Topical Cyclobenzaprine Hydrochloride Formulations
Bryson Evan
, Hartman Rachel, Arnold John, Gorman Greg, Sweitzer Sarah.Asbill Scott
Mar/Apr 2015
Pg. 161-166

Drug Therapy for Acute and Chronic Pain in the Cat
Lascelles B Duncan
Sep/Oct 2002
Pg. 338-343

Update on Managing Neuropathic Pain
McNulty Jack P
, Muller George
May/Jun 2009
Pg. 182-190

Topical Ketamine 10% for Neuropathic Pain in Spinal Cord Injury Patients: An Open-Label Trial
Rabi Joseph
, Minori Joshua, Abad Hasan, Lee Ray, Gittler Michelle
Nov/Dec 2016
Pg. 517-520

Pain: Systematic Review of Pharmacy Compounding of Pain Medication
Shawaqfeh Mohammad S
, Harrington Catherine
Jan/Feb 2018
Pg. 19-24

Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Hong Eun Ji
, Sumanasekera Wasana, Le Uyen Minh
Jan/Feb 2022
Pg. 65-71

A Brief Survey on Prescriber Beliefs Regarding Compounded Topical Pain Medications
Warner Meredith
, Tuder Dmitry
May/Jun 2014
Pg. 182-188

Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management
Rodriguez Franklin
, Carvalho Maria, Banov Fabiana
Nov/Dec 2023
Pg. 468-473

Levorphanol for the Treatment of Severe Chronic Pain
McNulty Jack P
May/Jun 2007
Pg. 202-211

Topical Treatment of Neuropathic Pain
Vadaurri Vince
May/Jun 2008
Pg. 182-190

Compounded Topical Gabapentin for Neuropathic Pain: Does Choice of Base Affect Efficacy?
Shakshuki Ayah
, Agu Remigius U
Nov/Dec 2019
Pg. 496-503

Return to Top